[Cold atmospheric pressure plasma for the treatment of acute and chronic wounds].

Kaltes Atmosphärendruckplasma zur Behandlung akuter und chronischer Wunden.
Blood flow enhancement Disinfection Plasma medicine Tissue regeneration Wound healing

Journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
ISSN: 1432-1173
Titre abrégé: Hautarzt
Pays: Germany
ID NLM: 0372755

Informations de publication

Date de publication:
Nov 2020
Historique:
pubmed: 1 10 2020
medline: 11 11 2020
entrez: 30 9 2020
Statut: ppublish

Résumé

Besides acute wounds (through trauma or surgical interventions), chronic wounds comprise a relatively large and heterogeneous group of diseases. These include leg ulcers with venous disease greatly prevailing arterial disease, diabetic foot syndrome, and pressure ulcers. Due to a considerable treatment resistance against such therapies, new and effective, additive treatment options especially for chronic wounds are needed. Wound treatment with cold atmospheric plasma (CAP) constitutes such an innovative option. Current research regarding the efficacy of cold plasma for healing of acute and chronic wounds is summarized. The literature on CAP applications in wound healing has been screened and reviewed. With CAP, several effects that promote wound healing can be simultaneously applied in one application. On the one hand, CAP exerts a strong and broad antimicrobial activity against biofilm. On the other hand, the plasma cocktail, which consists of reactive nitrogen and oxygen species, UV, and charged particles (electrical current), mediates tissue-stimulating, blood flow-promoting, and anti-inflammatory effects. Marked germ reduction on wounds and accelerated wound healing have already been convincingly demonstrated in controlled clinical studies. The comprehensive CAP study landscape with structured case report summaries and randomized case-control studies allows the conclusion that CAP is safe, effective, and easy to handle for wound treatment. The utilization of CAP in addition to standard wound treatments is starting to enter routine clinical practice.

Sections du résumé

BACKGROUND BACKGROUND
Besides acute wounds (through trauma or surgical interventions), chronic wounds comprise a relatively large and heterogeneous group of diseases. These include leg ulcers with venous disease greatly prevailing arterial disease, diabetic foot syndrome, and pressure ulcers. Due to a considerable treatment resistance against such therapies, new and effective, additive treatment options especially for chronic wounds are needed. Wound treatment with cold atmospheric plasma (CAP) constitutes such an innovative option.
OBJECTIVES OBJECTIVE
Current research regarding the efficacy of cold plasma for healing of acute and chronic wounds is summarized.
MATERIALS AND METHODS METHODS
The literature on CAP applications in wound healing has been screened and reviewed.
RESULTS RESULTS
With CAP, several effects that promote wound healing can be simultaneously applied in one application. On the one hand, CAP exerts a strong and broad antimicrobial activity against biofilm. On the other hand, the plasma cocktail, which consists of reactive nitrogen and oxygen species, UV, and charged particles (electrical current), mediates tissue-stimulating, blood flow-promoting, and anti-inflammatory effects. Marked germ reduction on wounds and accelerated wound healing have already been convincingly demonstrated in controlled clinical studies.
CONCLUSIONS CONCLUSIONS
The comprehensive CAP study landscape with structured case report summaries and randomized case-control studies allows the conclusion that CAP is safe, effective, and easy to handle for wound treatment. The utilization of CAP in addition to standard wound treatments is starting to enter routine clinical practice.

Identifiants

pubmed: 32997219
doi: 10.1007/s00105-020-04696-y
pii: 10.1007/s00105-020-04696-y
doi:

Substances chimiques

Plasma Gases 0

Types de publication

Case Reports Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

855-862

Auteurs

S Emmert (S)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland. steffen.emmert@med.uni-rostock.de.

A van Welzen (A)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

K Masur (K)

ZIK plasmatis, Leibniz Institut für Plasmaforschung und Technologie e. V. (INP), Greifswald, Deutschland.

T Gerling (T)

ZIK plasmatis, Leibniz Institut für Plasmaforschung und Technologie e. V. (INP), Greifswald, Deutschland.

S Bekeschus (S)

ZIK plasmatis, Leibniz Institut für Plasmaforschung und Technologie e. V. (INP), Greifswald, Deutschland.

C Eschenburg (C)

Orthopädie-Technik-Service aktiv GmbH, Greifswald, Deutschland.

P Wahl (P)

Diaspective Vision GmbH, Pepelow, Deutschland.

T Bernhardt (T)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

M Schäfer (M)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

M L Semmler (ML)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

N Grabow (N)

Institut für Biomedizinische Technik, Universitätsmedizin Rostock, Rostock, Deutschland.

T Fischer (T)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

A Thiem (A)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

O Jung (O)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

L Boeckmann (L)

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH